Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure

Background Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact of cost nor how to integrate cost into medica...

Full description

Bibliographic Details
Main Authors: Birju R. Rao, Candace D. Speight, Larry A. Allen, Scott D. Halpern, Yi‐An Ko, Daniel D. Matlock, Miranda A. Moore, Alanna A. Morris, Laura D. Scherer, Mary C. Thomson, Peter Ubel, Neal W. Dickert
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.121.023789